Clovis Oncology Inc (NASDAQ:CLVS)

Recently, shares of Clovis Oncology, Inc. Piper Jaffray maintained Clovis Oncology Inc (NASDAQ:CLVS) on Monday, November 16 with "Neutral" rating. The brokerage now has $72.00 target price on the biopharmaceutical company's stock. "(CLVS)" was reported by Transcript Daily and is the sole property of of Transcript Daily. Credit Suisse Group reaffirmed an "outperform" rating and set a $74.00 price objective on shares of Clovis Oncology in a research note on Tuesday, April 18th.

What does the Income statement say about Clovis Oncology Inc (NASDAQ:CLVS)? Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company's stock worth $116,000 after buying an additional 758 shares during the last quarter.

06/19/2017 - Clovis Oncology, Inc. had its "buy" rating reiterated by analysts at Stifel Nicolaus. They noted that the move was a valuation call. The company now has a consensus rating of Buy and an average price target of $72.40.

Relative strength index (RSI-14) for Clovis Oncology, Inc. The average numbers of shares are traded in a security per day, during the recent 3-month period.

Biotech stocks had "their best day since February" on June 19, 2017 with SPDR S&P Biotech ETF (XBI - Free Report) adding about 3.6% on the day. iShare Nasdaq Biotech ETF (IBB - Free Report) too gained 2.41%on June 19 (see all Health Care ETFs here). The stock has a 50-day moving average of $56.20 and a 200 day moving average of $56.21. The lowest 12-month price target for the shares is $50.00, which would be decrease of about -44% of its current value. Clovis Oncology also was the recipient of unusually large options trading activity on Monday. The See Remarks now owns $11,572,780 of the stock according to the SEC filing. During its last trading session, Stock traded with the total exchanged volume of 5.92 million shares. Clovis Oncology, Inc. (NASDAQ:CLVS) for the trailing twelve months paying dividend with the payout ratio of 0.00% to its shareholders. The company had revenue of $7.05 million for the quarter, compared to analyst estimates of $6.04 million. The consensus recommendation by Thomson Reuters analysts is and their mean rating for the stock is 2.00 on scale of 1-5. "(CLVS) Upgraded to Buy at Janney Montgomery Scott" was first published by Chaffey Breeze and is owned by of Chaffey Breeze. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/06/21/clovis-oncology-inc-clvs-receives-overweight-rating-from-j-p-morgan-chase-co.html.

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction dated Monday, May 15th.

The average 1-year price target for Clovis Oncology, Inc. Over the last 90 days, insiders have sold 9,000 shares of company stock valued at $495,690.

Other research analysts also recently issued research reports about the stock. For the quarter, shares are performing at 37.28%. Legacy Private Trust Co. purchased a new position in Clovis Oncology during the first quarter worth approximately $255,000. State Street Corp now owns 2,141,663 shares of the biopharmaceutical company's stock worth $95,131,000 after buying an additional 1,035,917 shares during the period. Finally, Endurant Capital Management LP boosted its stake in shares of Clovis Oncology by 73.1% in the first quarter. Driehaus Capital Management LLC acquired a new position in Clovis Oncology during the first quarter valued at $1,019,000. Clough Capital Partners L P boosted its stake in shares of Clovis Oncology by 0.6% in the first quarter. Wellington Management Group LLP now owns 1,331,669 shares of the biopharmaceutical company's stock worth $84,788,000 after buying an additional 1,318,669 shares during the last quarter. Hedge funds and other institutional investors own 97.55% of the company's stock.

Clovis Oncology, Inc.is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets.

  • Joanne Flowers